The world of thyroid treatment is at a pivotal moment. If you're one of the millions who rely on Natural Desiccated Thyroid (NDT) medications like Ren Thyroid, you’ve probably felt the shift. Between evolving FDA regulations and increasing patient demand for NDT over synthetic options, there’s a lot happening behind the scenes—and your health could be directly affected.
In the latest episode of the Modern Thyroid and Wellness Podcast, McCall McPherson, PA-C, sits down with Jeff Moshal, CEO of Genus Lifesciences, to talk about where things really stand. And let’s just say: this episode is packed with insight, advocacy, and hope.
NDT medications have been around since the 1800s—yes, before the FDA existed. But now, the FDA is cracking down, requiring formal approval for these “grandfathered” medications. That means companies like Genus Lifesciences have until August 2026 to get their products approved—or risk being pulled from the market.
⚠️ Millions of Americans could lose access to a thyroid medication that actually works for them.
McCall and Jeff break down what this means, why it’s happening, and what Genus is doing to protect access for patients who don’t respond well to synthetic thyroid meds.
Ren Thyroid isn’t just another NDT option. It’s built on rigorous science, U.S.-based sourcing, and exceptional quality control. Genus has created new strengths for more precise dosing, maintained a traceable supply chain (every pig is tracked from birth!), and invested years into FDA compliance—all while keeping patient outcomes front and center.
“We’re not just trying to get approval. We’re trying to raise the bar.”
— Jeff Moshal, CEO of Genus Lifesciences
If you’ve ever been told to “just take levothyroxine,” you’re not alone. But for many patients, T4-only medications aren’t enough. NDT offers both T4 and T3, and for some people, that’s the missing piece of the puzzle.
Patients report:
Here’s where it gets even more exciting. McCall and Jeff introduce The Thyroid Health Alliance—a new advocacy group formed to ensure patients never lose access to NDT. Their mission? Keep Ren Thyroid (and other NDTs) on the market while helping the FDA understand the real-life impact of these meds.
🗣️ You can help by sharing your story, joining the alliance, and staying informed.
This conversation isn’t just about policy. It’s about patient empowerment. Here’s what you can do now:
Whether you're newly diagnosed or have been managing your thyroid for decades, this moment matters. This episode reminds us that science, advocacy, and patient voices must all come together to shape the future of thyroid care.
🎧 Tune in now to hear the full story behind Ren Thyroid, what’s coming next, and how you can be part of the change.
